Decibel Therapeutics

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to developing therapies that restore inner ear sensory cells to treat hearing and balance disorders. Leveraging industry-leading single-cell genomics capabilities and proprietary gene therapy technologies, Decibel has built the world’s first comprehensive research, discovery, and drug development platform aimed at restoring hearing and balance functions. Decibel's pipeline, including its lead gene therapy program for treating congenital monogenic deafness (DB-OTO) and ototoxicity prevention program, aims to realize the vision of a world where everyone enjoys the privileges of hearing and balance.